To: (10)(2e))"[(10)(2e) @minvws.nl]; (10)(2e))[(10)(2e) @minvws.nl]; (10)(2e) (2 (10)(2e) .
((10)(2e))[(10)(2e) @minvws.nl]
From: (10)(2e)-(10)(2e)x(10)(2e)
Sent: Wed 7/15/2020 8:52:16 AM
Subject: RE: Moderna - NEJM publication
Received: Wed 7/15/2020 8:52:18 AM

Hallo (10)(2e),

Dank. Ik ga me inlezen.

Groet, (10)(2e)

(10)(2e) Centre for Immunology of Infectious Diseases and Vaccines |
National Institute for Public Health and the Environment (RIVM) | Antonie van Leeuwenhoeklaan 9 |
PO box 1 | 3720 BA BILTHOVEN | The Netherlands
T: +31 (10)(2e) M: +31 (0 (10)(2e) E: (10)(2e) @rivm.nl

From: (10)(2e)) < (10)(2e) @minvws.nl>
Sent: woensdag 15 juli 2020 10:47
To: (10)(2e) }10)(2e)10)(2e < (10)(2e) @rivm.nl>; (10)(2e)) <(10)(2e)@minvws.nl>; (10)(2e) 1' (10)(2e) (10)(2e)
< (10)(2e) @minvws.nl>
Subject: FW: Moderna - NEJM publication

Hallo (10)(2e) fijn dat je er vanuit RIVM bij kan zijn, hierbij informatie vooruit

Groet, (10)(2e)

Van: (10)(2e) @ec.europa.eu < (10)(2e) @ec.europa.eu>
Verzonden: woensdag 15 juli 2020 09:19
Aan: (10)(2e)@infarmed.pt; (10)(2e) @ec.europa.eu; (10)(2e) @sozialministerium.at; (10)(2e) @fagg-afmps.be; (10)(2e) @bda.bg; (10)(2e)@phs.moh.gov.cy; (10)(2e) @unob.cz; (10)(2e) @bmg.bund.de; (10)(2e)@dkma.dk; (10)(2e) @sm.ee; (10)(2e) @moh.gov.gr; (10)(2e) @aemps.es; (10)(2e) @formin.fi; (10)(2e) (10)(2e) @pm.gouv.fr; (10)(2e) @miz.hr; (10)(2e) @emmi.gov.hu; (10)(2e) @hse.ie; (10)(2e) @sanita.it; (10)(2e) @vvkt.lt; (10)(2e) @ms.etat.lu; (10)(2e) @vmnvd.gov.lv; (10)(2e) @gesundheitsministerium.gv.at; (10)(2e) @sozialministerium.at; (10)(2e) @gov.mt; (10)(2e)) <(10)(2e)@minvws.nl>; (10)(2e)) < (10)(2e) @minvws.nl>; (10)(2e) @urpl.gov.pl; (10)(2e) @ms.ro; (10)(2e) @gov.se; (10)(2e) (10)(2e) @gov.si
CC: (10)(2e) @gesundheitsministerium.gv.at; (10)(2e) @bmg.bund.de; (10)(2e) @aemps.es; (10)(2e) (10)(2e) @pm.gouv.fr; (10)(2e)@kontozamanis.gr'; (10)(2e) @gmail.com; (10)(2e) @sanita.it; (10)(2e)) <(10)(2e)@minvws.nl>; (10)(2e) @pzh.gov.pl; (10)(2e) @gov.se; (10)(2e) @mzv.sk'; (10)(2e) (10)(2e) @ec.europa.eu; (10)(2e) @ec.europa.eu; (10)(2e) @ema.europa.eu; (10)(2e) @ec.europa.eu; (10)(2e) @ec.europa.eu; (10)(2e) @ec.europa.eu; (10)(2e) @ec.europa.eu; (10)(2e) (10)(2e) @ec.europa.eu; (10)(2e) @ec.europa.eu; (10)(2e) @ec.europa.eu; (10)(2e) @ec.europa.eu; (10)(2e) @ec.europa.eu; (10)(2e) @ec.europa.eu
Onderwerp: Moderna - NEJM publication

Dear Board Members

Moderna have asked me to pass on the information attached to you, which may be of interest ahead of this afternoon's scientific meeting with them.

Regards,

(10)(2e)

(10)(2e)
(10)(2e)
(+32) (10)(2e)

Dear (10)(2e),

As per your request, on behalf of Moderna, I am pleased to be able to share with you our peer reviewed Phase I data, published today in the New England Journal of Medicine. This was done in collaboration with National Institutes of Health (NIH) and I have also attached our press release and copies of the editorial and publication. The study assessed safety and immunogenicity in interim results with mRNA-1273, our vaccine candidate against COVID-19.

I wanted to take this occasion to remind you of Moderna's commitment as a leading mRNA player in the market, especially in Europe. European partners, investors and citizens have been part of Moderna from the beginning and have played a key role in getting our mRNA technology to where it is today.

This Phase I trial was led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), under its own, independent Investigational New Drug (IND) application. This collaboration leveraged the expertise of both organisations and allowed the study to begin with incredible speed in light of the urgent public health priority that COVID-19 poses.

In follow up to our recent conversations, I felt this would be of interest and importance to inform your discussions, as you continue to consider the role of mRNA-1273 as part of the portfolio of solutions in response to COVID-19. Thank you for your kind offer to share this information with those experts who may benefit from this important data (it may be useful to share this with the experts who will be participating in the webex call that has been scheduled for Wednesday with Dr. Stephen Hoge, President of Research at Moderna.

I would be more than happy to direct you or interested parties, to members of the Moderna clinical or regulatory teams to discuss this with you in more detail if you are interested,

Kind regards

(10)(2e)